Bloomage Biotech(SH:688363) Jin Rong Jie·2026-02-02 01:48Core Viewpoint - Huaxi Biological announced an expected net profit of 270 million to 320 million yuan for 2025, representing a year-on-year growth of 54.93% to 83.63% [1] - The growth is attributed to a systematic transformation rather than short-term scale expansion, focusing on "agile management, growth, and efficiency" [1][3] Financial Performance - The net profit excluding non-recurring gains is projected to be between 167 million and 217 million yuan, with a year-on-year increase of 55.68% to 102.29% [1] - Management expenses are expected to decrease by over 10% year-on-year in 2025 [1] Operational Strategy - The company emphasizes professional development and optimizes its business structure and resource allocation, leading to a sales expense reduction of over 30% [2] - Cost and expense management has been refined to support profit growth [2] Innovation and Digital Transformation - Huaxi Biological focuses on scientific research as its core competitive advantage, particularly in glycoscience and cell biology [2] - The company is enhancing its industrialization capabilities in bioactive substances and regenerative materials through a synthetic biology research and development system [2] - Continuous digital transformation is improving operational efficiency across all business scenarios, including AI integration in various functions [2] Long-term Development - The 2025 performance growth reflects the company's commitment to high-quality development and core capability building [3] - The company aims to maintain its competitive advantage through technological innovation and a comprehensive industrial layout [3]